Loading organizations...
Founded in 2011 by Daniel Gibson, Todd Nelson, and Craig Venter, San Diego, California-based Codex DNA develops automated synthetic biology tools like the innovative BioXp benchtop system. The biotechnology company helps academic and commercial researchers rapidly design, code, synthesize, and print genes, having rebranded from SGI-DNA to reflect its DNA coding mission. Operating as a public enterprise under the NASDAQ ticker DNAY, the firm generated $2.8 million in revenue during the third quarter of 2021 and currently holds 65 patents. The organization employs approximately 140 people who support proprietary hardware, software, and biofoundry services for applications in drug discovery, genome editing, and precision medicine. To expand its operational footprint, Codex DNA acquired Eton Bioscience for $13 million and established strategic licensing agreements with major pharmaceutical partners like Pfizer for enzymatic DNA synthesis technology.
Codex DNA has raised $25.0M across 1 funding round.
Codex DNA has raised $25.0M in total across 1 funding round.
Codex DNA has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series A in September 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 9, 2019 | $25M Series A | Northpond Ventures | BroadOak Capital Partners, Oxford Finance | Announced |
Codex DNA has raised $25.0M in total across 1 funding round.
Codex DNA's investors include Northpond Ventures, BroadOak Capital Partners, Oxford Finance.
